Drugs / MK-4618
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01337674 | Apr → Nov 2011 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4618 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01337674 ↗ |
| Route | Oral | “Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7” NCT01337674 ↗ |